The role of substance P in depression: therapeutic implications by Schwarz, Markus J. & Ackenheil, Manfred
Substance P (for “powder”), identified as a gut
tachykinin in 1931 and involved in the control of multiple
other autonomic functions, notably pain transmission, is
the focus of intense fundamental and clinical psychiatric
research as a central neurotransmitter, neuromodulator,
and immunomodulator, along with sister neurokinins A
and B (NKA and NKB), discovered in 1984. Substance P is
widely distributed throughout the central nervous sys-
tem, where it is often colocalized with serotonin, nor-
epinephrine, and dopamine. Many neurokinin (NK)
receptor antagonists and agonists have been synthesized
and some clinically tested. A double-blind study of
MK869, a selective NK1 receptor antagonist that blocks
the action of substance P, showed significant activity ver-
sus placebo and fewer sexual side effects than paroxetine
in outpatients with major depression and moderate anx-
iety. Substance P, which is degraded by the angiotensin-
converting enzyme (ACE), may mediate modulation of
therapeutic outcome in affective disorders by functional
polymorphism within the ACE gene: the D allele is asso-
ciated with higher ACE levels and increased neuropep-
tide degradation, with the result that patients with
major depression who carry the D allele have lower
depression scores and shorter hospitalization. ACE poly-
morphism genotyping might thus identify those patients
with major depression likely to benefit from NK1 recep-
tor antagonist therapy.
n the 1960s, the first tricyclic antidepressant
drugs were found to act by blocking the reuptake of the
classical neurotransmitters serotonin (5-hydroxytrypt-
amine [5-HT]) and norepinephrine (NE).
1 Since then,
these two monoamine neurotransmitters have been the
focus of antidepressant drug research and the most com-
mon pathophysiological concepts of major depression
are based on this profile of antidepressant action.
Increasing knowledge has indicated that the modula-
tion of monoamines is not the only mechanism for anti-
depressant actions. Neuropeptides, which are colocal-
ized with monoamines, could also be involved in the
pathophysiology of depression.Substance P (SP),which
was first detected 70 years ago,came into play in recent
years.In 1998,there was an exciting report in the journal
Science by Kramer et al showing the antidepressant
activity of an SP receptor antagonist.
2 In the following,
we will give a comprehensive overview of the nature of
SP, the neuropeptide family it belongs to, and current
data regarding the activity of SP receptor antagonists
as psychotropic drugs.
Substance P and the tachykinin family
SP was the first known neuropeptide. Von Euler and
Gaddum isolated SP from extracts of intestine and from
brain as one of many substances.As it was in the pow-
dered form,they named it substance P.In the first exper-
iments,SP stimulated contractions of rabbit-ileum in an
atropine-resistant manner. This first report on SP was
published in 1931.
3 In 1953,SP was recognized as a sen-
sory neurotransmitter by Lembeck et al.
4 It was more
than 10 years later that SP was isolated from bovine
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Dialogues Clin Neurosci. 2002;4:21-29.hypothalamus and sequenced by Susan Leeman and col-
leagues,culminating her efforts to identify a tissue com-
ponent that stimulates salivation in rats.
5 Another 10
years later, the other two mammalian tachykinins were
discovered: the cationic peptide neurokinin A (NKA,
formerly named substance K) and the anionic peptide
neurokinin B (NKB).
6-8
The tachykinins (tachys = swift) evoke a sharp contrac-
tion of the smooth muscle of the gut.
9These tachykinins
are involved in multiple physiological processes, as
demonstrated by their widespread distribution. In the
periphery,they function as potential regulators of blood
flow, vascular permeability, salivation, gastrointestinal
motility,intestinal secretion,micturition,and leukocyte
activity. Moreover, they act as pain transmitters from
the periphery. In the central nervous system (CNS),
tachykinins act as neurotransmitters and neuromodu-
lators.
Tachykinin genes and synthesis
There are two genes encoding for the synthesis of the
three tachykinins SP, NKA, and NKB: the prepro-
tachykinin I (PPTI) gene encodes for SP and NKA,
while the PPTII gene encodes for NKB.
10Through alter-
native splicing,the PPTI gene can express four different
forms (α, β, γ, and δ) of mRNA.All of these forms are
precursors of substance P, but only the β and γ forms
also encode for the synthesis of NKA and its elongated
forms neuropeptide K and neuropeptide γ.
11-13 Transla-
tion of the mRNA generates the so-called grandfather
peptide, the prepropeptide. The enzymatic cleavage to
the “paternal” propeptide is done inside the endoplas-
mic reticulum.The last step in generating the active pep-
tide is carried out by converting enzymes in cytoplas-
mic vesicles.Once the neuropeptides have been released,
they are inactivated by catabolic peptidases. The
tachykinins are degraded by multiple peptidases in the
tissue including the angiotensin-converting enzyme
(ACE).
14,15 There is no reuptake mechanism, as known
for the monoamine neurotransmitters.
16
Anatomic distribution of tachykinins 
within the CNS
SP is widely distributed throughout the CNS and the
myenteric and submucous nerve plexuses of the gut. In
the brain, SP is found in the midbrain periaquaeductal
gray, nucleus raphe magnus, and nucleus reticularis
gigantocellularis pars α,which are important structures
in the endogenous pain control system.
17 Large numbers
of SP-containing neurons have been found in the human
posterior hypothalamus and basal forebrain, indicating
an involvement of SP in hypothalamic functions such as
sexual behavior or pituitary hormone release.
18 SP is also
found in the basal ganglia, nucleus accumbens, and—in
lower levels—in the cerebral cortex.
19 Moreover,there is
evidence that SP interacts with dopaminergic neurons of
nigrostriatal, limbic, and forebrain nuclei.
20 NKB neu-
rons are present in the anterior hypothalamus and the
basal forebrain, indicating a complementary distribu-
tion from SP neurons.
18All three tachykinins are repre-
sented in the corpus striatum.
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Colocalization of substance P with other 
neurotransmitters in the brain
In the human brain,5-HT and SP coexist in a substantial
proportion of the cell population of the dorsal raphe
nucleus,the current target for antidepressant drug treat-
ment.
22,23Almost 50% of the serotonergic neurons in the
dorsal raphe nucleus, projecting to the forebrain, and
25% of the serotonergic neurons in the median raphe
nucleus express SP mRNA.
23 SP and 5-HT are colocal-
ized in cat ventral medullary neurons
24 and in seroton-
ergic neuronal afferents to the hypoglossal nucleus of
the rat.
25 Moreover,SP is coexpressed with the serotonin
receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 in rat
striatum.
26 It is remarkable that the expression of SP in
the striatum, substantia nigra, and amygdala is reduced
after chronic treatment with the antidepressant drugs
imipramine,desipramine,clomipramine,amoxapine,and
mianserin.Imipramine and desipramine also reduce the
amount of SP in the hippocampus,while its reduction in
the septum is only induced by mianserin.
27
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Selected abbreviations and acronyms
ACE angiotensin-converting enzyme 
FM fibromyalgia syndrome 
5-HT 5-hydroxytryptamine (serotonin)
ICV intracerebroventricular
NE norepinephrine
NKA neurokinin A
NKB neurokinin B
SP substance P23
The colocalization of SP and NE is demonstrated by the
existence of SP-containing axon terminals in the locus
ceruleus.
28 Direct application of SP to the locus ceruleus
has an excitatory effect via the neurokinin NK1 recep-
tor.
29-31
SP is also colocalized with dopaminergic neurons in the
nucleus accumbens.
32 SP is under the stimulatory control
of dopaminergic neurons, projecting to the substantia
nigra pars compacta and to the internal segment of the
globus pallidus.
33 Blockade of dopaminergic transmis-
sion by reserpine decreases the levels of SP mRNA,
since it is under the stimulatory control of dopamine.
34
Chronic treatment with amphetamine was found to be
without effect on dopamine receptor levels in the stria-
tum, but markedly increased the SP mRNA levels.
34
Some studies suggest that the pain-suppression system
involving the activation of mesolimbic dopaminergic
neurons is naturally triggered by exposure to stress,
through the endogenous release of opioids and SP in
the midbrain.
35
SP is also coexpressed with a wide variety of other neu-
ropeptides and neurotransmitters, and even with neu-
ronal nitric oxide synthase.
36
Neurokinin receptors
Three distinct neurokinin receptors are known: NK1,
NK2,and NK3.SP is the most potent tachykinin for the
NK1 receptor,whereas NKA exhibits the highest affin-
ity for the NK2 receptor and NKB for the NK3 recep-
tor.
37 Recently, the NK4 receptor, which was initially
claimed to be an atypical opioid receptor,was shown to
respond potently to NKB in the rat,
38 but its detection in
human tissue has not been possible to date.
39 However,it
must be pointed out that all mammalian tachykinins
have limited selectivity for a particular neurokinin
receptor.
40This is due to the common C-terminal amino
acid sequence,which is essential for the biological activ-
ity of the tachykinins.
41
The neurokinin receptors are G-protein–coupled recep-
tors with the characteristic seven-membrane–spanning
domains.
9 In general, several mechanisms prevent the
uncontrolled stimulation of cells by neurotransmitters
that interact with G-protein–coupled receptors: (i)
removal of the agonist from the extracellular fluid by
degradation or reuptake (the latter is not relevant to
the tachykinins, as stated above); (ii) desensitization of
the receptor by uncoupling from the G-proteins to ter-
minate the signal transduction cascade; and (iii) endo-
cytosis of the agonist-stimulated receptor,depleting the
plasma membrane of high-affinity receptors.
42The NK1
receptor appears to be desensitized by phosphorylation,
independently of receptor internalization, while resen-
sitization requires endocytosis, recycling, and dephos-
phorylation.
43,44 The prompt tachyphylaxis of the NK1
receptor after exposure to the agonist is,however,linked
to the rapid receptor internalization.
45
Anatomic distribution of neurokinin 
receptors within the CNS
A wide variety of brain regions express the NK1 receptor.
Notably, the raphe nuclei, locus ceruleus, striatum, the
nucleus accumbens,the hippocampus,the lateral nucleus
of the hypothalamus, the habenula, the interpeduncular
nucleus,the nucleus of the tractus solitarius,and the sub-
stantia nigra are all rich in NK1 receptors.
46-48Thus,there is
a remarkable mismatch between SP-containing brain
regions and NK1 receptor–expressing brain regions,
which may be due to the aforementioned limited selec-
tivity of the tachykinins. NK2 receptors are sparsely dis-
tributed in the CNS.They can be found in low amounts in
various regions, such as the striatum. The third type of
neurokinin receptor,the NK3 receptor,is strikingly preva-
lent in midcortical laminae throughout the cortex.
The patterns of expression are therefore very different
between the NK1,NK2,and NK3 receptors.NK4 recep-
tor mRNA is widely expressed in neurons in the rat
CNS,including cerebral cortex,hippocampus,and hypo-
thalamus.
49 The NK1 receptor is also coexpressed with
nitric oxide synthase in striatal interneurons in the rat.
50
In the spinal cord, NK1 receptors are localized on sec-
ond-order sensory neurons,receiving nociceptive inputs.
The NK1 receptor signal induces a slowly developing
sustained depolarization,while the fast input to second-
order sensory neurons is mediated by the excitatory
amino acid glutamate through the N-methyl-D-aspar-
tate (NMDA) receptor.
37
Specific actions of the neurokinin receptors
Elliott and Iversen described the diverse effects of SP
after intracerebroventricular (ICV) administration or
direct application into the ventral tegmental area of the
mesencephalon of rat brain, which caused increased
locomotor activity, grooming behavior, and wet dog
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51 Repetitive hind paw tapping was also shown
to result from activation of central NK1 receptors in
gerbils.
52 SP locally injected into the caudal pontine retic-
ular nucleus dose-dependently increases the amplitude
of the acoustic startle response in rats.
53
Not only simple movements are induced by SP. Even
complex behavior in animal models of anxiety and
depression can be modulated by NK receptor activa-
tion.ICV infusion of the SP analogue,dimethyl-C7,was
found to produce aversion in a place-conditioning para-
digm.
54 Moreover, ICV administration of SP, NKA, and
NK1- and NK2-selective agonists produces an anxio-
genic effect in the plus-maze test, the mouse model for
anxiety behavior.
55 In contrast,the synthetic NK3 agonist
senktide has an anxiolytic effect.
56 This again demon-
strates the differential role of the three NK receptors.
However,the complexity of the tachykinin system is also
represented by differential effects within one NK recep-
tor subtype, as the same receptor can exert contrary
effects upon stimulation in different brain regions.One
example is the anxiogenic effect of SP microinjection
into the rat periaqueductal gray,
57 whereas injection into
the nucleus basalis produces an anxiolytic effect.
58
Maternal separation of guinea-pig pups was shown to
cause internalization of the NK1 receptors in the baso-
lateral nucleus of the amygdala, suggesting the binding
of SP to its receptor as a response to separation stress.
2
In contrast,administration of the NK1 receptor agonist
GR73632 induced pronounced long-lasting audible
vocalizations,that could be attenuated by pretreatment
with the antidepressant drug imipramine.
2 To demon-
strate the direct relationship between NK1 receptors
and anxious behavior, the gene coding for the NK1
receptor was manipulated by deleting the first two trans-
membrane domains of the receptor molecule. This
genetic disruption of the NK1 receptor markedly
reduced anxiety-related behavior in the elevated plus-
maze, novelty-suppressed feeding, and maternal sepa-
ration paradigms.
59 However,knock-out mice that totally
lacked the NK1 receptor did not exert changed anxiety-
related behavior in the open field test, but were
markedly less aggressive than NK(+/+) mice in the res-
ident intruder test of aggression.
60 Consistent with these
data,SP has been shown to evoke defensive rage in cats
through an amygdalo-hypothalamic pathway.
61 Systemic
or intrahypothalamic infusion of the NK1 receptor
antagonist CP96345 blocked this defensive rage
62 in a
similar manner to tricyclic antidepressants.
63
Besides its role in modulating behavior, SP also exerts
an important immunomodulating role within the CNS.
Local administration of SP increases the interferon-γ
(IFN-γ)–induced upregulation of antigen-presenting
major histocompatibility complex (MHC) molecules in
the brainstem, while administration of an NK1 recep-
tor antagonist has the opposite effect.
64 Moreover, SP
has the potency to influence the so-called T helper 1/
T helper 2 (Th1/Th2) balance in the peripheral immune
system, leading to the breakdown of the commitment
to a particular T helper cell type.
65This is most interest-
ing, as a predominance of the Th1-like, IFN-γ–related
immune response was proposed in major depression.
66 In
summary, the immunomodulatory potency of SP may
be a relevant component in the pathophysiology of
major depression.
Neurokinin receptor antagonists
The first peptidergic NK1 receptor antagonists were syn-
thesized in the early 1980s as useful tools for the inves-
tigation of the endogenous NK1 ligands.
67 Ten years
later, Snider and colleagues established the first non-
peptide NK1 receptor antagonist.
68 It was the first step in
the race for a pharmacological compound to antagonize
the SP signal. It was only 2 years later that the binding
epitopes of SP and the new antagonist were detected
69:
the tachykinin binds to the extracellular loops of the
receptor, while the nonpeptide antagonists bind more
deeply in the transmembrane segments of the receptor
molecule.In the meantime,a great variety of nonpeptide
antagonists for the NK1,NK2,and NK3 receptors have
become available.
Basic pharmacological studies on neurokinin
receptor antagonists
The important modulating and enhancing role of SP in
nociception led to the idea of introducing NK1 receptor
antagonists as antinociceptive drugs.A lot of effort was
made toward the development of NK1 receptor antago-
nists for the treatment of pain.Although NK1 receptor
antagonists appeared to act synergistically to inhibit
NMDA receptors on second-order sensory neurons,they
exhibited only weak potency in acute pain.
70 However,
antinociceptive efficacy could be observed in nociceptive
models of chronic pain. This may be relevant to the
treatment of the fibromyalgia syndrome (FM), a syn-
24
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drome, characterized by chronic widespread pain and
depression-like symptoms. Serum and cerebrospinal
fluid (CSF) levels of SP are increased in FM,suggesting
its probable role in the pathophysiology of FM.
71 We
were able to demonstrate a relationship between SP lev-
els and intensity of pain perception in FM patients.
72
Thus,the therapeutic use of NK1 receptor antagonists in
FM may be a successful treatment strategy in FM,
although they have failed to show antinociceptive effi-
cacy in other chronic pain syndromes like peripheral
neuropathy,osteoarthritis,or migraine.
73
Since central administration of SP was shown to induce
depression-like and anxious behavior (see above), the
NK1 receptor antagonists were tested in several animal
models of depression and anxiety.Vocalization evoked
in guinea-pig pups or neonatal mice by transient mater-
nal separation could be attenuated by systemic admin-
istration of several NK1 receptor antagonists, such as
CP99994, L760735, or L733060.
2,74 This effect was com-
parable to that of clinically used antidepressants
(phenelzine, imipramine, fluoxetine) and anxiolytics
(diazepam,buspirone).The dose-dependent antidepres-
sant-like effect of another NK1 receptor antagonist,
NKP608, was demonstrated in the chronic mild stress
model of depression in rats,where the magnitude of the
effect was similar to antidepressants in clinical use, but
with a faster onset of action.
75 The same NK1 receptor
antagonist also exerted anxiolytic efficacy in rat social
interaction tests.
76 As shown by microinjection experi-
ments of NK1 receptor antagonists, the amygdala
appears to be one of the sites of action.
77
More evidence for the antidepressant activity of NK1
receptor antagonists is given by their modulation of the
serotonergic and norepinephrinergic systems. Systemic
administration of an NK1 receptor antagonist enhances
the firing rate of the locus ceruleus in response to
stress.
28 Recently,the activating effect of sustained NK1
receptor blockade on postsynaptic 5-HT1a autorecep-
tors was shown.
78 The functional relationship between
the NK1 receptor and the serotonergic system was also
demonstrated by studies on NK1 knock-out mice. The
constitutive lack of NK1 receptors appeared to be asso-
ciated with a downregulation and functional desensiti-
zation of 5-HT1a autoreceptors.The serotonin receptor
subtype 1a has been suggested to be critically involved in
antidepressant action of selective serotonin-reuptake
inhibitors (SSRIs) and its downregulation and desensi-
tization in NK1 knock-out mice is equivalent to the
effect of chronic treatment with SSRI antidepressants.
79
Studies using NK1 receptor antagonists are not the only
ones to show the anxiolytic and antidepressant potency
of antagonizing the tachykinin receptors.The selective
blockade of the NK2 receptor also exhibited the
potency of antidepressant-like action.A recently pub-
lished study demonstrated the positive effect of the
NK2 receptor antagonist SR48968 on the mobility in
the forced swimming test in mice and rats, and on the
maternal separation–induced vocalizations in guinea-
pig pups. This behavioral effect was associated with a
reduced separation-induced increase in the number of
neurons displaying NK1 receptor internalization in the
amygdala.
80 In contrast,the NK3 receptor seems to play
a differential role in depression-like behavior: another
recent study using the forced swimming test as mouse-
model of depression showed the positive effect of the
NK3 receptor agonist aminosenktide. Stimulation of
the NK3 receptor shortened the time of immobility to
the same extent as the prototypic antidepressant
desipramine in two out of three investigated mouse
lines.
81 The anxiolytic effect of NK3 receptor agonists
had already been shown by the elevated plus-maze
test.
56 These antidepressant-like and anxiolytic poten-
cies of NK3 agonist properties may be related to the
activation of the endogenous opioid system through
NK3 receptor stimulation, as shown previously.
82
Clinical pharmacological studies 
on neurokinin receptor antagonists
In 1998,Mark Kramer and colleagues published the first
report of a clinical study testing the antidepressant effi-
cacy of an NK1 receptor antagonist.
2 This randomized,
double-blind, placebo-controlled and active (paroxe-
tine)–controlled study investigated the safety and effi-
cacy of MK869, a selective NK1 receptor antagonist.
This study has been subject of several more or less
extensive reviews and commentaries,
73,83-85 and so we will
just give a short overview of the most important findings
here. Outpatients with major depressive disorder and
moderately high anxiety levels received a single daily
dose of 300 mg MK869 (n=66),20 mg paroxetine (n=68),
or a placebo (n=64) for 6 weeks in four different study
centers.Efficacy measurements were made at the end of
weeks 1, 2, 4, and 6 by the Hamilton Depression scale
total score (HAM-D21) and the Clinical Global Impres-
sions Severity (CGI-S) scale.The principal outcome wasa 4.3-point difference between MK869 and placebo on
the HAM-D21 score,confirming the antidepressant effi-
cacy of MK869. This NK1 receptor antagonist also
demonstrated significant anxiolytic efficacy in the
depressed patients. MK869 was well tolerated and,
notably, the incidence of sexual dysfunction was 23%
lower than in patients receiving paroxetine.These data
encouraged the researchers to conduct a large dose-find-
ing study of the same compound in patients with major
depression, but the findings of this second study were
not definitive due to the high placebo response rate.
86
Despite this sobering result, these workers continued
to prove the concept of NK1 receptor antagonism as a
treatment strategy in major depression and carried out
a clinical study with a second,more potent NK1 recep-
tor antagonist,wich they called “compound A.”Outpa-
tients with a diagnosis of major depression with melan-
cholic features received either a daily dose of
compound A (n=66) or a placebo (n=62) for 6 weeks in
a randomized, double-blind, placebo-controlled study.
The results were presented at the 2001 annual Ameri-
can College of Neuropsychopharmacology (ACNP)
meeting.
87 The mean decrease from baseline in HAM-
D17 total score was 10.7 points in the verum group,
whereas the placebo group exhibited an improvement
of 7.8 points. Statistical analysis showed that this dif-
ference of 2.9 points reflected a significantly more pro-
nounced improvement in patients who received com-
pound A (P<0.009). Mean scores on the CGI-I scale
also improved significantly in favor of compound A
(P<0.009). Compound A appeared to be safe and well
tolerated. The indices for sexual side effects and gas-
trointestinal symptoms were similar to those observed
in the placebo group. The authors concluded that SP
antagonism is a generally well-tolerated antidepressant
mechanism.
87
A third NK1 receptor antagonist, NKP608, is currently
in phase 2 clinical trials as an antidepressant drug,but no
data have been published on its efficacy to date.
Aspects for the future
Our results indicate the possible influence of a functional
polymorphism within the ACE gene on the therapeutic
outcome in affective disorders.
88As stated above,ACE is
one of the SP-degrading enzymes. About 50% of the
interindividual ACE concentration is determined by an
insertion/deletion polymorphism of the ACE gene,
89 with
the D-allele being associated with higher ACE levels
90
and increased neuropeptide degradation.
91 Our findings in
patients with major depression demonstrate that D-allele
carriers show markedly lower scores on the Hamilton
depression scale,remitted more often,and had a shorter
duration of hospitalization.This relationship between the
genotype of the SP-degrading enzyme and both severity
of depression and treatment response suggests the poten-
tial role of SP in the pathophysiology of major depression.
Genotyping of this ACE polymorphism might help to
identify those patients with major depression, who are
predisposed to NK1 receptor antagonists.❑
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El papel de la sustancia P en la depresión y
implicaciones terapéuticas
La sustancia P (por “polvo”), identificada como una
taquiquinina intestinal en 1931 e involucrada en el
control de otras múltiples funciones autonómicas,
especialmente en la transmisión del dolor, es el
foco de una intensa investigación básica y en psi-
quiatría clínica como un neurotransmisor, neuro-
modulador e inmunomodulador central, junto a
las neuroquininas hermanas A y B (NKA y NKB),
descubiertas en 1984. La sustancia P se distribuye
extensamente a través del sistema nervioso central,
donde a menudo se co-localiza con serotonina,
noradrenalina y dopamina. Se han sintetizado
muchos agonistas y antagonistas de receptores de
neuroquininas (NK) y algunos de ellos se han eva-
luado clínicamente. Un estudio doble ciego de
MK869, un antagonista selectivo del receptor NK1
que bloquea la acción de la sustancia P demostró
actividad significativa al compararlo contra el pla-
cebo y menos efectos sexuales colaterales que la
paroxetina en pacientes ambulatorios con depre-
sión mayor y ansiedad moderada. La sustancia P,
que es degradada por la enzima convertidora de
angiotensina (ECA), puede mediar la modulación
de la evolución terapéutica de los trastornos afec-
tivos a través del polimorfismo funcional dentro
del gen de la ECA: el alelo D se asocia con niveles
más elevados de ECA y un aumento en la degra-
dación del neuropéptido. Esto se traduce en que
pacientes con depresión mayor que poseen el alelo
D tienen puntajes menores de depresión y hospi-
talizaciones más breves. La determinación genéti-
ca del polimorfismo de la ECA podría así identificar
a aquellos pacientes con depresión mayor que pro-
bablemente se beneficiarían con una terapia con
antagonistas del receptor NK1.
Rôle de la substance P dans la dépression :
implications thérapeutiques
La substance P (pour poudre), identifiée comme
une tachykinine intestinale en 1931 et impliquée
dans le contrôle de nombreuses autres fonctions
autonomes, en particulier la transmission de la
douleur, a suscité d'intenses recherches cliniques et
fondamentales en psychiatrie en tant que neuro-
transmetteur, neuromodulateur et immunomodu-
lateur central, parallèlement aux neurokinines
sœurs A et B (NKA, NKB), découvertes en 1984. La
substance P est largement répandue dans le systè-
me nerveux central où elle coexiste souvent avec la
sérotonine, la noradrénaline et la dopamine. De
nombreux agonistes et antagonistes des récepteurs
aux neurokinines (NK) ont été synthétisés et pour
certains cliniquement testés. Une étude en double
aveugle du MK869, un antagoniste sélectif du
récepteur NK1 qui bloque l’action de la substance
P, a montré une activité significative vs placebo et
moins d’effets secondaires d’ordre sexuel que la
paroxétine chez les patients ambulatoires souf-
frant d’une dépression sévère et d’une anxiété
modérée. La substance P, qui est dégradée par l’in-
hibiteur de l’enzyme de conversion de l’angioten-
sine (IEC), pourrait médier la modulation de l’évo-
lution thérapeutique des troubles affectifs par un
polymorphisme fonctionnel au sein du gène de
l’IEC : l’allèle D est associé à des concentrations plus
élevées d’IEC et une augmentation de la dégrada-
tion des neuropeptides ; par conséquent les
patients souffrant d’une dépression sévère et por-
teurs de l’allèle D présentent des scores de dépres-
sion plus faibles et des hospitalisations plus courtes.
Le génotypage du polymorphisme des IEC pourrait
ainsi permettre d’identifier les patients ayant une
dépression sévère susceptibles de bénéficier au
mieux d’un traitement par antagonistes des récep-
teurs aux NK1.Basic research
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